Difference between revisions of "I-123 Biomarker Committee"
Jump to navigation
Jump to search
| Line 8: | Line 8: | ||
==Recent Meetings/Call Summaries== | ==Recent Meetings/Call Summaries== | ||
| + | |||
| + | *[[Media:2018_11-16_QIBA_SPECT_I-123_Call Summary-FINAL.pdf | November 16, 2018]] | ||
*[[Media:2018_08-17_QIBA_SPECT_I-123_Call Summary-FINAL.pdf | August 17, 2018]] | *[[Media:2018_08-17_QIBA_SPECT_I-123_Call Summary-FINAL.pdf | August 17, 2018]] | ||
Revision as of 19:15, 18 January 2019
- Co-chairs: John Dickson, PhD; John Seibyl, MD
- Secretary: Julie Lisiecki
Quantifying Dopamine Transporters with 123Iodine Labeled Ioflupane in Neurodegenerative Diseases
Recent Meetings/Call Summaries
Profile Development
Reference Materials
- QIBA SPECT I-123 Biomarker Committee Presentation (11.16.2018) John Seibyl, MD